Results 161 to 170 of about 2,863,474 (344)

Lead Toxicity Mitigation: Sustainable Nexus Approaches [PDF]

Nitish Kumar, Amrit Kumar Jha
openalex   +1 more source

BGP-15 Protects against Doxorubicin-Induced Cell Toxicity via Enhanced Mitochondrial Function [PDF]

, 2023
Alexandra Gyöngyösi, Nikolett Csaki, Ágota Pető, Kitti Szőke, Ferenc Fenyvesi, Ildikó Bácskay, István Lekli   +6 more
openalex   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source

Essential Trace and Toxic Element Content in Lacaune Sheep Milk during Lactation [PDF]

, 2023
Zvonko Antunović, Boro Mioč, Josip Novoselec, Ivan Širić, Valentino Držaić, Željka Klir Šalavardić   +5 more
openalex   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source

Immunotherapy toxicities: An SGO clinical practice statement [PDF]

, 2022
Roisin E. O’Cearbhaill, Leslie H. Clark, Ramez N. Eskander, Stéphanie Gaillard, John W. Moroney, Elena Pereira, Bhavana Pothuri   +6 more
openalex   +1 more source

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source

Research on Adverse Outcome Pathway (AOP) Development For chemical-induced and life factor-induced liver Disease

Safety and Health at Work, 2022
Hye-Yeon Choi, Yong-Hoon Lee
doaj   +1 more source

Toxicity of microwave-assisted biosynthesized zinc nanoparticles in mice: a preliminary study [PDF]

, 2019
Azad Salimi, Hamid Reza Rahimi, Hamid Forootanfar, Elham Jafari, Atefeh Ameri, Mojtaba Shakibaie   +5 more
openalex   +1 more source

Flows and budgets of nutrients and potentially toxic elements on four Swedish organic farms using digestate from agricultural residues [PDF]

, 2022
Eva Salomon, Pernilla Tidåker, Sara Nilsson   +2 more
openalex   +1 more source